

Radiopharm Theranostics Limited notice to prospective investors – website disclaimer

1 Important notice

The information on this page is not part of the Prospectus or Supplementary Prospectus. You must read this notice before you attempt to access the electronic version of the Prospectus and Supplementary Prospectus on this website and indicate your agreement at the bottom of this notice. If you agree to these conditions, you will be given access to the electronic Prospectus and Supplementary Prospectus.

2 Date and duration of Offer

Radiopharm Theranostics Limited ACN 647 877 889 (**Radiopharm**) lodged a Prospectus and Supplementary Prospectus for an offer of 83,333,333 shares in Radiopharm to raise \$50 million at an offer price of \$0.60 per share (**Offer**) with the Australian Securities & Investments Commission on 14 October 2021 and 28 October 2021 respectively. The Prospectus and Supplementary Prospectus details the terms of the Offer. The Offer period commences on 29 October 2021 and is expected to close on 5 November 2021. Radiopharm may vary these dates without notice.

3 Applications not accepted until offer period commences

Applications for Radiopharm shares under the Prospectus and Supplementary Prospectus will not be accepted by Radiopharm until 29 October 2021 when the offer period commences. Applications may only be made on the Application Forms attached to or accompanying the Prospectus (including the electronic copy of the Prospectus). Applications will not be processed until after the offer period commences and no preference will be conferred on Applications received prior to commencement of the offer period. Radiopharm will not accept a completed Application Form if it has reason to believe that (a) the applicant has not received a complete paper copy or the electronic copy of the Prospectus and Supplementary Prospectus, or (b) the Application Form or electronic copy of the Prospectus and Supplementary Prospectus has been altered or tampered with in any way.

4 Jurisdiction

Access to the electronic version of the Prospectus and Supplementary Prospectus is only available to persons resident in Australia with a registered address in Australia, from within Australia. The distribution of this Prospectus and Supplementary Prospectus in jurisdictions outside of Australia may be restricted by law and persons in such jurisdictions who come into possession of the Prospectus and Supplementary Prospectus should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. The Prospectus and Supplementary Prospectus does not constitute an offer or an invitation in any jurisdiction in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register the Prospectus and Supplementary Prospectus, or otherwise permit a public offering of Radiopharm's shares, in any jurisdiction outside Australia. The Prospectus and Supplementary Prospectus provided on the Radiopharm website is available to persons accessing this website from within Australia only. If you are accessing this site from anywhere outside Australia, do not download, print or view the Prospectus and Supplementary Prospectus accessible through this web page. By accessing the Prospectus and Supplementary Prospectus, you acknowledge and confirm that you are accessing this website from within Australia.

5 Investors should seek advice

Nothing contained on this website or in the Prospectus and Supplementary Prospectus constitutes investment, legal, business, tax or other advice. If you are in doubt as to how to deal with the Prospectus, Supplementary Prospectus or Application Form, please contact your accountant, lawyer, stockbroker or other professional adviser. The Prospectus and Supplementary Prospectus contains information relevant to a decision to invest in shares and the risks associated with that investment. You should read the entire Prospectus and Supplementary Prospectus carefully before applying for shares.

6 Privacy

To access the electronic version of the Prospectus and Supplementary Prospectus you may be required to provide personal information to Radiopharm. Radiopharm collects, holds and will use that information to assess your Application (should you make one) and to communicate and provide services to you. Radiopharm may disclose information to its agents, related bodies corporate, associates, service providers (such as the share registry) and government bodies. You may access, correct and update the personal information that Radiopharm holds about you by contacting the share registry.

7 Acceptance of conditions

By proceeding, I agree to the above statements, and confirm that I am a resident of Australia accessing this website from within Australia. In addition, I represent, warrant and agree that I am not a resident of the United States or currently located in the United States, nor am I acting for the account or benefit of any person in the United States, a US person or

any other foreign person, and that I will not make a copy of the Prospectus and Supplementary Prospectus available to, or distribute a copy of the Prospectus to, any such non-Australian resident person.

[Agree] [I do not agree]